Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials
Conclusions
Vasopressin receptors antagonists may reduce body weight and increase Na but do not improve all-cause mortality, cardiovascular mortality or kidney function. In addition, acceptability of long-term treatment side effects and hospitalization appears problematic.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Cardiology | Cardiovascular | Heart | Heart Failure | Stroke | Study | Urology & Nephrology